Tag: LUCO
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40
All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40
